1st Counsel – Lifestyle
Author:
Cerevance, Inc.
Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting
April 9, 2026
Cerevance to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with Solengepras in Parkinson’s Disease at AD/PD™ 2026
March 10, 2026